K

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Associate Director - Statistical Programming

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • Proven hands-on experience in programming for clinical development, preferably in a leadership role, with a strong preference for late-phase clinical trial support.
  • Experience in regulatory submissions, including NDAs, BLAs, and other filings; experience in ISS/ISE is highly desirable.
  • Expertise in SAS programming and comprehensive knowledge of CDISC standards.
  • Familiarity with ICH/GCP guidelines and global regulatory submission requirements, such as FDA and EMA requirements.
  • Extensive experience overseeing CROs, including independent validation of datasets and statistical deliverables.
  • An advanced degree (MS or PhD) in Biostatistics, Statistics, or a related field.
  • For candidates with an MS, a minimum of 8 years of relevant experience; for candidates with a PhD, a minimum of 6 years of relevant experience.

Responsibilities

  • Lead statistical programming efforts for clinical studies, including developing and reviewing programming specifications to ensure clarity, integrity, and compliance with internal and external standards.
  • Lead the execution of ad-hoc and post-hoc analyses to support emerging clinical questions, publications, and internal decision-making.
  • Oversee and coordinate activities with Contract Research Organizations, focusing on implementing CDISC standards, creating SDTM and ADaM datasets and TFLs, and ensuring high-quality deliverables.
  • Conduct independent validation and quality checks of statistical programming deliverables from CROs.
  • Collaborate with statisticians and cross-functional study teams to deliver results accurately and on time.
  • Manage multiple projects simultaneously and prioritize tasks to meet deadlines.

Desired Qualifications

  • A background in cardiometabolic diseases or related therapeutic areas is preferred.

About the Company

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Kailera Therapeutics focuses on obesity and related metabolic conditions by acquiring and developing clinical-stage drug candidates and moving them toward commercialization. Its lead asset, KAI-9531, is an injectable dual agonist of GLP-1 and GIP receptors for obesity and type 2 diabetes, and the pipeline includes an oral GLP-1 agonist (KAI-7535), an oral tablet form of KAI-9531, and an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors (KAI-4729). The company differentiates itself by sourcing assets outside of early research, pursuing a mix of injectable and oral therapies, and leveraging a high-profile leadership team and substantial funding to progress a broad portfolio under external licenses. Kailera’s goal is to advance multiple metabolic disease therapies from clinical development toward commercialization to improve outcomes for patients with obesity and related conditions.

Company size
51-200
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Kailera Therapeutics

See more jobs